AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2893190
Drug: Short-course prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-course prednisone therapy
Trial: 8482290
Drug: Standard prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard prednisone therapy
Trial: 28185318
Drug: Calcineurin Inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin Inhibitor (CNI)
Trial: 26603745
Drug: Self-management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management of blood pressure (self-monitoring with self-titration of antihypertensive medication)
Trial: 25091790
Drug: De-escalation of
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation of empirical antimicrobial treatment
Trial: 25091790
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of empirical antimicrobial treatment
Trial: 2776869
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg terbutaline from a Turbuhaler inhaled as fast as possible (mean peak inspiratory flow rate = 53 l.min-1)
Trial: 2776869
Drug: Simple inhalation
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple inhalation technique with terbutaline Turbuhaler
Trial: 735294
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous Propranolol
Trial: 735294
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous Metoprolol
Trial: 31083176
Drug: Venlafaxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine treatment for 6 weeks
Trial: 19783397
Drug: BCTS-S inhalation
RxNorm normalized name: S-2 Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCTS-S inhalation of 5 mg morphine HCl
Trial: 19783397
Drug: BCTS-MC inhalation
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCTS-MC inhalation of 5 mg morphine HCl
Trial: 16444450
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d pravastatin
Trial: 7971538
Drug: Life-style modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-style modification program (5 weekly 90-min sessions on modifying eating and exercise patterns)
Trial: 3528451
Drug: Pressure-controlled probing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-controlled probing (50 g vertical force)
Trial: 15998266
Drug: Zinc citrate/triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc citrate/triclosan formulation with bromochlorophene
Trial: 15998266
Drug: Zinc citrate/triclosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc citrate/triclosan formulation without bromochlorophene
Trial: 11360593
Drug: Diet control
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet control and insulin therapy (treated group)
Trial: 8685072
Drug: Fluvoxamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150 mg day(-1))
Trial: 8685072
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg day(-1))
Trial: 8685072
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (TCA or neuroleptic treatment without SSRI)
Trial: 31618444
Drug: Guideline-concordant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-concordant treatment
Trial: 30478103
Drug: Online Climate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Climate Schools: Ecstasy and Emerging Drugs module (4 lessons over 4 weeks)
Trial: 30478103
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose (completed all four lessons)
Trial: 30478103
Drug: Incomplete dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incomplete dose (≤three lessons)
Trial: 27469482
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) HF therapy
Trial: 27469482
Drug: NT‐proBNP guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP guided therapy (goal NT‐proBNP <1000 pg/mL)
Trial: 24023318
Drug: 5‐fluorouracil (5‐FU)/l‐leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU)/l‐leucovorin (LV)/CPT‐11 (FOLFIRI) regimen
Trial: 12975721
Drug: Low-dose diuretics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, dihydropyridine calcium antagonists
Trial: 22658300
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Trial: 12975721
Drug: Multiple antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple antihypertensive drugs
Trial: 9380472
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil suspension 15 mg/kg
Trial: 24824648
Drug: AS03A-adjuvanted H1N12009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose)
Trial: 24824648
Drug: AS03A-adjuvanted H1N12009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03A-adjuvanted H1N12009 pandemic influenza vaccine (single dose plus booster)
Trial: 12056293
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d sulfasalazine
Trial: 10692750
Drug: Cefaclor AF
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor AF (750 mg b.d.)
Trial: 10692750
Drug: Amoxycillin/clavulanate (875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (875/125 mg b.d.)
Trial: 1768223
Drug: Low-dose estrogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen oral contraceptive pills
Trial: 6790206
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg, i.v. administration)
Trial: 26121830
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid therapy
Trial: 26121830
Drug: Postauricular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postauricular steroid therapy
Trial: 19805701
Drug: Oral naltrexone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral naltrexone, 50 mg/d for 6 months (plus placebo implants)
Trial: 19805701
Drug: Naltrexone implant,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone implant, single dose of 2.3 g (plus placebo tablets)
Trial: 9649989
Drug: droperidol 0.05
RxNorm normalized name: fentanyl citrate/droperidol 0.05-2.5MG INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.05 mg
Trial: 9649989
Drug: droperidol 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.10 mg
Trial: 9649989
Drug: droperidol 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.15 mg
Trial: 9649989
Drug: droperidol 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.20 mg
Trial: 7853676
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) 20 mg/kg administered via intravenous bolus injection or 30‐minute intravenous drip infusion 3 times daily for 3‐11 days
Trial: 7853676
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) 20 mg/kg
Trial: 26056119
Drug: TCZ-SC 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ-SC 162 mg weekly + placebo-IV every four weeks
Trial: 26056119
Drug: TCZ-IV 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ-IV 8 mg/kg every four weeks + placebo-SC weekly
Trial: 26056119
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who switched formulations
Trial: 23342783
Drug: Umbilicus moxibustion
RxNorm normalized name: Umbilicus rupestris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilicus moxibustion therapy plus Jingui Shenqi Pill (8 pills, 3 times a day)
Trial: 23342783
Drug: Jingui Shenqi
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jingui Shenqi Pill (8 pills, 3 times a day)
Trial: 16043683
Drug: Enalapril maleate,
RxNorm normalized name: Enalapril Maleate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril maleate, 5 to 40 mg/d
Trial: 11377599
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m², day 1) and cisplatin (80 mg/m², day 2)
Trial: 11377599
Drug: Gemcitabine (1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1100 mg/m², days 1 and 8) and docetaxel (100 mg/m², day 8)
Trial: 2529776
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic hormone (ANH) infusion at 0.47 pmol.kg‐1.min‐1 for 2.5 hours
Trial: 28011387
Drug: Immediate intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate intensive non-surgical periodontal treatment
Trial: 28011387
Drug: Rescue treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue treatment with delayed intensive treatment
Trial: 25195169
Drug: Anakinra (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (1 mg/kg, maximum 100 mg)
Trial: 21507295
Drug: TNF‐α treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α treatment (1.0 ng/mL)
Trial: 26275480
Drug: TNF‐α treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α treatment
Trial: 17105853
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg etanercept (ETN)
Trial: 17105853
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg etanercept (ETN)
Trial: 15629872
Drug: Reboxetine 8
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 8 mg/day
Trial: 28478996
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (risperidone, olanzapine, quetiapine)
Trial: 30653856
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) supplementation (280 mL/d for 8 days)
Trial: 28223259
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AED) administered from 4 days before surgery until 1 month after surgery
Trial: 25060406
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (100 to 1600 mcg) during a 26-day open-label titration period
Trial: 26509361
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray
Trial: 19934866
Drug: Milrinone (phosphodiesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (phosphodiesterase 3 inhibitor)
Trial: 3505192
Drug: 1 alpha
RxNorm normalized name: antiCD11 alpha
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 alpha (OH)D3 + Ca 1.0 g/day
Trial: 3505192
Drug: Ca 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca 1.0 g/day
Trial: 29016275
Drug: Psychoanalytic-Interactional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic-Interactional Therapy (PIT)
Trial: 26808580
Drug: Expert Psychodynamic
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expert Psychodynamic Therapy (E-PDT)
Trial: 26808580
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (treatment as usual/waiting for treatment)
Trial: 22750188
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) self‐help volume
Trial: 10205101
Drug: Adrenaline 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.25 ml (1:1000)
Trial: 16206598
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bisoprolol and analapril with trimetazidine (70 mg/day for 6 months)
Trial: 16206598
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bisoprolol and analapril
Trial: 8527283
Drug: TRH 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH 0.5 mg
Trial: 8527283
Drug: TRH 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH 1.0 mg
Trial: 8527283
Drug: RX77368 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX77368 1 mg
Trial: 1730831
Drug: Oral provocation
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral provocation with alpha-amylase
Trial: 27154462
Drug: MedSentry remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedSentry remote medication monitoring system
Trial: 19724055
Drug: Deferasirox (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (35 mg/kg single dose)
Trial: 17710426
Drug: Isotretinoin daily
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin daily for the first month, then first 10 days of each month for 5 months (group 2)
Trial: 17710426
Drug: Isotretinoin daily
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin daily for 6 months (group 3)
Trial: 11495074
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of lansoprazole once daily for 5 days
Trial: 9778202
Drug: ACE-I treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I treatment
Trial: 9778202
Drug: No ACE-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACE-I treatment
Trial: 2407872
Drug: Diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem SR monotherapy
Trial: 9649912
Drug: Hydrochlorothiazide monotherapy
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide monotherapy
Trial: 2407872
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Diltiazem SR + Hydrochlorothiazide)
Trial: 4064778
Drug: Bovine heparin
RxNorm normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine heparin
Trial: 4064778
Drug: Porcine heparin
RxNorm normalized name: Porcine heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine heparin
Trial: 7404480
Drug: Bovine heparin
RxNorm normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine heparin and Porcine heparin
Trial: 31758080
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific regimen not detailed)
Trial: 14970894
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar pharmacological treatments)
Trial: 7004956
Drug: Dantrolene sodium
RxNorm normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dantrolene sodium suspension
Trial: 25475771
Drug: Platelet-rich fibrin
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich fibrin (PRF) treatment
Trial: 20144497
Drug: Non-PRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PRF treatment (control)
Trial: 18032083
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine administered in the morning
Trial: 15309229
Drug: Late phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late phototherapy (started when transcutaneous bilirubin reached 8 mg/dl, suspended when bilirubin fell to 5 mg/dl)
Trial: 11557835
Drug: Bupropion (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (100 mg/d with gradual increase to 200 mg twice daily)
Trial: 9631781
Drug: Early extubation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early extubation (EE) with reduced dose of fentanyl (15 microg/kg)
Trial: 8187295
Drug: Levothyroxine 0.1
RxNorm normalized name: LEVOTHYROXINE 0.1MG/ML ORAL SOLN UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine 0.1 mg daily (Group A)
Trial: 9882992
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group B)
Trial: 2886820
Drug: Intravenous dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dihydroergotamine (DHE)
Trial: 31206358
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (rosuvastatin)
Trial: 26632101
Drug: Azilsartan Medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan Medoxomil (AZL-M) 20, 40, and 80 mg QD
Trial: 26632101
Drug: Chlorthalidone (CLD)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (CLD) 12.5 and 25 mg QD
Trial: 23329787
Drug: Enteral L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral L-arginine supplementation (1.5 mmol/kg/d bid)
Trial: 21119151
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for personality disorders (CBT-PD)
Trial: 19066155
Drug: Ti6A17Nb-alloy (girotan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ti6A17Nb-alloy (girotan L)
Trial: 14604568
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, 15 microg of each protein given at first and second injection (4 weeks apart)
Trial: 14604568
Drug: Combination B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, No sulphadoxine-pyrimethamine (SP)
Trial: 14604568
Drug: SP+vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP+vaccine
Trial: 30265039
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) for attending treatment for 6 weeks
Trial: 30265039
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) for attending treatment for 7-12 weeks
Trial: 11952542
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulphate at a dose of 10 mg kg(‐1) daily up to 600 mg day(‐1)
Trial: 9861126
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg with Droperidol 1.25 mg
Trial: 7624737
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) 6 g daily (6 enterosoluble tablets of 500 mg AA, twice a day)
Trial: 7624737
Drug: Placebo (tartaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tartaric acid, TA) 2.55 g daily (213 mg TA, twice a day)
Trial: 2151405
Drug: Triptorelin (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.2 mg monthly for 6 months)
Trial: 2151405
Drug: Buserelin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (900 micrograms daily for 6 months)
Trial: 360561
Drug: Cefadroxil 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 1,000 mg. twice daily
Trial: 360561
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg. four times a day
Trial: 31177906
Drug: Selective ETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective ETA receptor antagonist, sitaxentan
Trial: 28655128
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping along with conventional treatment